Publication
Response to Idelalisib in a Patient with Stage IV Merkel-Cell Carcinoma.
Authors not recorded
N Engl J Med2015PMID 26466009PMC4652581stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMerkel Cell Carcinomacivic_curation1.00
- drugIdelalisibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA P471Lcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26466009
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA P471L1 | ||||||||
| Idelalisib | Merkel Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 3 | accepted | EID739A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib. PMID 26466009 · Shiver et al., 2015 · Open in CIViC | civic |